ASCO 2020: Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was…
Browsing: ivosenidib
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- Novel “Hydrogel” Carriers for Anti-Cancer Drugs Offer New Hope for Cancer Treatment!
- Scientists uncover mutations that make cancer resistant to therapies targeting KRAS
- Discovery could revive failed treatments for solid tumours
- Breast cancer survivors’ fear of cancer returning linked to genomic testing, psychological factors
- What are the risk factors for experiencing side effects from childhood cancer treatments?
- An amyloid link between Parkinson’s disease and melanoma
- Study revises understanding of cancer metabolism
- ‘Patchwork’ tumours prevalent across multiple cancer types
